Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027
[294 Pages Report] The global Leukapheresis products market is projected to reach USD 98.5 Million by 2027 from USD 65.6 Million in 2022, at a CAGR of 8.5% between 2022 and 2027. The global Leukopaks market is projected to reach USD 784.2 Million by 2027 from USD 146.9 Million in 2022, at a CAGR of 39.8% between 2022 and 2027.
The market is mainly driven by factors such as the rising global cases of blood cancers, especially leukemia, growing applications of leukopaks in research, and rise in the number of blood donations globally. However, the high cost of therapeutic leukapheresis and leukopaks, stringent donor recruitment criteria, the dearth of skilled professionals, the low adoption of therapeutic leukapheresis, complications associated with therapeutic leukapheresis, the long procedural time for leukapheresis, the high cost of cellular immunotherapies, and a lack of favorable reimbursement are expected to restrain the growth of this market to a certain extent in the coming years.
Attractive Opportunities in the Leukapheresis Products Market
To know about the assumptions considered for the study, Request for Free Sample Report
Leukapheresis Market Dynamics
Drivers: Increasing number of blood donations
The global demand for blood and blood components is on the rise. According to the American Red Cross, approximately 21 million units of blood components are transfused every year in the US. The requirement for leukocytes/WBCs increases with the increase in demand for leukopaks in clinical research and the rising number of clinical trials for the development of CAR-T therapy for leukemia.
According to the WHO, in 2020, 79 countries worldwide have been collecting more than 90% of their blood supply from voluntary unpaid donors. This includes 60 self-sufficient countries that can completely meet the demand for donated blood from voluntary blood donations, including Iceland, Kenya, Nicaragua, Turkey, the UAE, and Zambia.
With the increase in the number of blood donations, the demand for apheresis devices for the separation of blood products and the development of leukopaks for clinical research is also expected to increase during the forecast period.
Restraints: Stringent donor recruitment criteria
To ensure the safety of blood donations for both donors and recipients, Red Cross societies across the globe have issued certain guidelines and eligibility requirements for blood donors, considering the ideal donor age, general health considerations, medical conditions, medical treatments, medications, vaccinations, as well as lifestyle and life events, in addition to choices such as tattoos and piercings.
However, the most important eligibility criterion for donating leukocytes is human leukocyte antigen typing. The human immune system uses these markers to distinguish between its own cells and foreign ones. As a result, HLA typing is typically performed during collection to ensure the specificity and easy identification of leukocytes.
These stringent criteria qualify a very small portion of the global population for leukocyte donation. Furthermore, only a very small segment of this regularly donates blood. The selection process gains stringency with regard to the donation of mobilized peripheral blood/leukocytes. Donors can donate non-mobilized leukocytes only six times in their lifetime and mobilized leukocytes twice. This limits the availability of mobilized leukopaks, which, in turn, significantly hampers the growth of the overall leukapheresis products and leukopaks market.
Opportunities: Leukapheresis for pediatric patients
Despite its therapeutic applications, the adoption of leukapheresis as a treatment, particularly for hyperleukocytic leukemia, is still low. However, the applications of therapeutic leukapheresis in the treatment of pediatric patients are becoming an area of focus for stakeholders in this sector. This can be mainly attributed to the side effects and risks of conventional treatments such as chemotherapy for children.
Moreover, according to the American Cancer Society, leukemia is the most common cancer detected in children and adolescents in the US (28% and 13%, respectively). The most common leukemias in children are ALL and AML, with the latter being more effectively treated by leukapheresis. Leukapheresis can be used for both the treatment/removal of excess WBCs in pediatric lymphoma patients and the collection of stem cells from children for other cancer patients. The possibilities and advantages of leukapheresis in this application make it an area of focus in this market. However, therapeutic leukapheresis has been uncommonly performed, particularly given that very few hospitals currently provide leukapheresis treatment for children in both developed and emerging markets.
Challenges: Blood transfusion safety in developing countries
WBC transfusions have been associated with the risks of transmitting infectious agents such as HIV, HBV, HCV, and malaria. Infection through the blood supply is a major issue, especially in developing countries such as India, China, Brazil, and Argentina, where economic constraints often limit safety considerations during WBC transfusion procedures.
Testing blood for HIV and hepatitis B viruses is an integral part of the blood transfusion process across the globe; moreover, the necessity of this step is more pronounced in developing countries, where the burden of these diseases is higher. Even though authorities in various developing countries are currently ensuring blood testing, according to the WHO, only 57% of hospitals performing transfusions have systems to report adverse events, and only 50% of reporting hospitals have transfusion committees. Moreover, in countries with greater malaria transmission, more than 30% of the blood donors can carry malaria parasites, which can be transmitted by transfusion. Thus, ensuring blood safety is a major challenge faced by blood and blood component suppliers and healthcare institutions in developing countries.
Ecosystem / Market Map
Centrifugal devices segment is expected to be the fastest growing segment of the leukapheresis devices market in the forecast period.
The centrifugal devices segment held the largest share of the leukapheresis devices market in 2021 along with being the fastest growing segment in the forecast period due to the increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis, favorable reimbursement policies for therapeutic apheresis, and the increasing use of centrifugal apheresis for blood component donations by blood centers and hospitals.
The research applications segment dominated the leukapheresis products market in 2021.
In 2021, the research applications segment was the largest segment of the leukapheresis products market. This can primarily be attributed to factors such as increasing adoption of leukapheresis products for the development of cell-based immunotherapies, the increasing demand for leukopaks in research, and the increasing adoption of leukapheresis-derived primary cells in drug development.
Asia Pacific expected to grow at the highest CAGR during the forecast period
In 2021, North America accounted for the largest share of the leukapheresis products market. Factors like strong presence of a large number of players and a large number of ongoing CAR T-cell therapy clinical trials contribute to stronghold of this region.
Additionally, the fastest growing region in the leukapheresis products market during the forecast period is the Asia Pacific. This growth is driven by factors such as the growing number of personalized medicine, regenerative medicine, cell therapy research activities, and increasing funding for CAR T-cell therapy research.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
Key players in the leukapheresis market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).
These companies adopted strategies such as service launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
:
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2020–2027 |
|
Base year considered |
2021 |
|
Forecast period |
2022–2027 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Leukapheresis Products – Type, application, end user, region |
|
Geographies covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Companies covered |
|
The research report categorizes the leukapheresis market into the following segments and subsegments:
Leukapheresis Products
- Product Type
- Leukapheresis Devices
- Centrifugal Devices
- Membrane Separators
- Leukapheresis Disposables
- Leukapheresis Devices
- Application
- Research Applications
- Therapeutic Applications
- End User
- Hospitals & Transfusion Centers
- Component Providers & Blood Centers
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
Leukopaks
- Type
- Mobilized Leukopaks
- Non-Mobilized Leukopaks
- Diseased Leukopaks
- Isolated PBMCs
- Indications
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Non-Hodgkin’s Lymphoma
- Multiple Myeloma
- Hepatocellular Carcinoma
- Pancreatic Cancer
- Other Indications
- End User
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Region
- North America
- US
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- Rest of Asia Pacific
- Rest of the World
- North America
Recent Developments
- In July 2022, Discovery Life Sciences (US) acquired AllCells (US) to strengthen the portfolio for critical starting materials and analytic services to accelerate Competitive Generic Therapy (CGT) applications.
- In January 2021, Lonza Group AG (Switzerland) launched cryopreserved high-quality leukopaks to its product portfolio.
- In December 2021, Discovery Life Sciences, Inc. (US) acquired In Vitro ADMET Laboratories, LLC (US) to expand its product portfolio in drug research and development through the expansion of its biospecimen offerings.
- In January 2020, Fresenius Kabi inaugurated an expansion of its transfusion and apheresis disposables plant in the Dominican Republic in Santa Domingo.
Frequently Asked Questions (FAQ):
Which is the largest segment in the leukapheresis market, by type?
By product type, the leukapheresis products are segmented into devices and disposables. Out of these, the larger share is occupied by the disposables segment in 2021. This can be attributed to recurrent use of disposables during leukapheresis procedures, and the increasing adoption of therapeutic leukapheresis procedures.
Which is the leading type of end user segment of Leukapheresis products market?
Based on end user, the blood component providers & blood centers segment accounted for the larger share of the Leukapheresis products market in 2021. The demand for leukapheresis products among blood component providers & blood centers is primarily driven by the increasing number of blood donations, the growing demand for leukopaks for the development of CAR T therapy, and the increasing demand for blood components in cancer research.
Who are the key players operating in the Leukapheresis market?
Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), and Terumo BCT, Inc. (US).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), and Charles River Laboratories International, Inc. (US).
Which geographical region is dominating in Leukapheresis market?
In 2021, North America dominated the Leukapheresis market, followed by Europe and the Asia Pacific. The large share of North America can be attributed to the developed health infrastructure in the US and Canada, and the rise in research activities related to leukopaks and CAR T therapy in the region. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 35)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 41)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET)
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET
FIGURE 6 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 8 REVENUE ANALYSIS OF THE TOP 4 COMPANIES: LEUKAPHERESIS MARKET (2020)
FIGURE 9 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
FIGURE 10 TOP-DOWN APPROACH
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET
FIGURE 11 VOLUME ESTIMATION OF LEUKOPAKS MARKET
FIGURE 12 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS (LEUKOPAKS MARKET)
FIGURE 13 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 14 MARKET DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 RESEARCH ASSUMPTIONS
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET
3 EXECUTIVE SUMMARY (Page No. - 58)
FIGURE 15 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 16 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 17 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 18 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 19 LEUKOPAKS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 20 LEUKOPAKS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 21 LEUKOPAKS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 22 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET
FIGURE 23 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET
4 PREMIUM INSIGHTS (Page No. - 65)
4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW
FIGURE 24 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY
FIGURE 25 LEUKAPHERESIS DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2021
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX
FIGURE 26 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX
FIGURE 27 NORTH AMERICA DOMINATED MARKET IN 2021
4.5 LEUKOPAKS MARKET: OVERVIEW
FIGURE 28 FAVORABLE GOVERNMENT SUPPORT AND RISING DEMAND FOR LEUKOPAKS IN RESEARCH APPLICATIONS TO DRIVE MARKET
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY
FIGURE 29 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2021
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX
FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.8 LEUKOPAKS MARKET: REGIONAL MIX
FIGURE 31 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 70)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 32 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of leukemia
FIGURE 33 ESTIMATED NUMBER OF NEW CASES OF LEUKEMIA, BY REGION (2020-2040)
FIGURE 34 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020-2040)
5.2.1.2 Increasing number of blood donations
5.2.1.3 Increased demand for leukopaks in clinical research
FIGURE 35 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009-2020
FIGURE 36 NUMBER OF CAR-T THERAPY CLINICAL TRIALS IN US V/S CHINA, 2022
5.2.2 RESTRAINTS
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks
TABLE 3 COST OF LEUKOPAKS, BY TYPE
5.2.2.2 Stringent donor recruitment criteria
TABLE 4 DONOR SELECTION CRITERIA
TABLE 5 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
5.2.2.3 Dearth of skilled professionals and low adoption of therapeutic leukapheresis
5.2.2.4 Complications associated with therapeutic leukapheresis
5.2.2.5 Long procedural time for leukapheresis
5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement
5.2.3 OPPORTUNITIES
5.2.3.1 Leukapheresis for pediatric patients
5.2.3.2 Emerging economies with investments from academic institutes, pharma-biotech companies, and leading players
5.2.3.3 Gaps in current leukapheresis technologies
5.2.4 CHALLENGES
5.2.4.1 Blood transfusion safety in emerging countries
5.3 PORTER’S FIVE FORCES ANALYSIS
FIGURE 37 PORTER’S FIVE FORCES ANALYSIS (2021): LEUKAPHERESIS MARKET
TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT FROM NEW ENTRANTS
5.3.2 THREAT FROM SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 INDUSTRY TRENDS
5.4.1 INCREASING NUMBER OF COLLABORATIONS AMONG PHARMA AND BIOTECH COMPANIES
TABLE 7 RECENT DEVELOPMENTS FOR CAR-T THERAPY
5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Centrifugal-based leukapheresis
5.5.1.2 Membrane-based leukapheresis
TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION
5.5.2 EMERGING TECHNOLOGIES
5.5.2.1 Adsorption-based leukapheresis
5.5.2.2 Microfluidic devices for leukapheresis
5.6 PRICING ANALYSIS (LEUKOPAKS MARKET)
TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS
TABLE 10 ASP OF MOBILIZED LEUKOPAKS
TABLE 11 ASP OF MOBILIZED ISOLATED CELLS
5.7 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 12 LEUKAPHERESIS MARKET: LIST OF CONFERENCES AND EVENTS
5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
5.8.3 ASIA PACIFIC
5.8.3.1 Japan
5.8.3.2 China
5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
5.10.1 US
TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS
5.10.2 EUROPE
5.10.3 JAPAN
5.10.4 INDIA
5.11 VALUE CHAIN ANALYSIS
FIGURE 38 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS)
5.12 SUPPLY CHAIN ANALYSIS
FIGURE 39 LEUKAPHERESIS MARKET: STAKEHOLDERS IN SUPPLY CHAIN
5.13 ECOSYSTEM ANALYSIS
FIGURE 40 LEUKAPHERESIS MARKET: ECOSYSTEM MAP (2021)
TABLE 19 LEUKAPHERESIS MARKET: ECOSYSTEM
5.14 PATENT ANALYSIS
5.14.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET
FIGURE 41 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET, JANUARY 2018–AUGUST 2022
5.14.2 PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET
FIGURE 42 GLOBAL PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET, JANUARY 2018–AUGUST 2022
5.14.3 TOP APPLICANTS (COMPANIES) FOR LEUKAPHERESIS PRODUCTS PATENTS
FIGURE 43 TOP APPLICANT COMPANIES FOR LEUKAPHERESIS PRODUCTS PATENTS, JANUARY 2018–AUGUST 2022
5.14.4 TOP APPLICANTS (COMPANIES) FOR LEUKOPAKS PATENTS
FIGURE 44 TOP APPLICANT COMPANIES FOR LEUKOPAKS PATENTS, JANUARY 2018–AUGUST 2022
5.14.5 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR LEUKAPHERESIS MARKET PATENTS
FIGURE 45 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2018–AUGUST 2022
FIGURE 46 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LEUKOPAKS PATENTS, JANUARY 2018–AUGUST 2022
5.14.6 LIST OF TOP PATENT APPLICANTS/OWNERS
FIGURE 47 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKAPHERESIS PRODUCTS PATENTS (JANUARY 2018–AUGUST 2022)
FIGURE 48 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKOPAKS PATENTS (JANUARY 2018–AUGUST 2022)
TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: LIST OF MAJOR PATENTS (2020-2021)
TABLE 21 LEUKOPAKS MARKET: LIST OF MAJOR PATENTS (2019 – 2022)
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 49 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS
TABLE 22 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS
5.15.2 BUYING CRITERIA
FIGURE 50 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS
TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS
5.16 ADJACENT MARKET ANALYSIS
5.16.1 PLASMA FRACTIONATION MARKET
FIGURE 51 PLASMA FRACTIONATION MARKET OVERVIEW
5.16.2 APHERESIS MARKET
FIGURE 52 APHERESIS MARKET OVERVIEW
6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE (Page No. - 110)
6.1 INTRODUCTION
TABLE 24 LEUKAPHERESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 25 LEUKAPHERESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2 LEUKAPHERESIS DISPOSABLES
6.2.1 RECURRENT USAGE AND DEMAND FOR DISPOSABLES TO BOOST SEGMENT
TABLE 26 SOME MANUFACTURERS OF LEUKOREDUCTION FILTERS
TABLE 27 SOME MANUFACTURERS OF LEUKAPHERESIS COLUMNS AND CELL SEPARATORS
TABLE 28 LEUKAPHERESIS DISPOSABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 LEUKAPHERESIS DEVICES
TABLE 29 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 30 LEUKAPHERESIS DEVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.1 CENTRIFUGAL DEVICES
6.3.1.1 Increasing installation in hospitals for therapeutic apheresis to drive market
TABLE 31 LIST OF SOME OF THE CENTRIFUGAL APHERESIS DEVICES AVAILABLE
TABLE 32 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 MEMBRANE SEPARATORS
6.3.2.1 Difficulties in separating huge volumes of plasma from milliliters of whole blood to limit market
TABLE 33 LIST OF SOME OF THE MEMBRANE SEPARATORS AVAILABLE
TABLE 34 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION (Page No. - 119)
7.1 INTRODUCTION
TABLE 35 LEUKAPHERESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2 RESEARCH APPLICATIONS
7.2.1 INCREASED CLINICAL TRIALS TO DRIVE SEGMENT
TABLE 36 COMPANIES INVOLVED IN DEVELOPMENT OF FDA-APPROVED CAR T-CELL THERAPIES
TABLE 37 LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 THERAPEUTIC APPLICATIONS
7.3.1 RISING ADOPTION OF LEUKAPHERESIS AS A SUPPORTIVE TREATMENT IN LEUKEMIA TO FUEL MARKET
TABLE 38 LEUKAPHERESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER (Page No. - 123)
8.1 INTRODUCTION
TABLE 39 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
8.2.1 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS TO DOMINATE LEUKAPHERESIS PRODUCTS MARKET
TABLE 40 LEUKAPHERESIS PRODUCTS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET
TABLE 41 LEUKAPHERESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT
TABLE 42 PHARMA-BIOTECH COMPANIES TO DEVELOP CAR T-CELL TECHNOLOGIES
TABLE 43 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 HOSPITALS & TRANSFUSION CENTERS
8.5.1 GROWING NUMBER OF HOSPITALS PERFORMING TRANSFUSIONS TO PROPEL SEGMENT
TABLE 44 LEUKAPHERESIS PRODUCTS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2020–2027 (USD MILLION)
9 LEUKOPAKS MARKET, BY TYPE (Page No. - 131)
9.1 INTRODUCTION
TABLE 45 LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 46 LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9.2 MOBILIZED LEUKOPAKS
9.2.1 MOBILIZED LEUKOPAKS TO DOMINATE MARKET
TABLE 47 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS
TABLE 48 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2020–2027 (UNITS)
9.3 NON-MOBILIZED LEUKOPAKS
9.3.1 LOW COST COMPARED TO MOBILIZED LEUKOPAKS TO PROPEL MARKET
TABLE 50 NUMBER OF CELLS IN A NON-MOBILIZED LEUKOPAK
TABLE 51 COMPARATIVE ANALYSIS OF MOBILIZED LEUKOPAKS AND NON-MOBILIZED LEUKOPAKS
TABLE 52 COMPOSITION OF MOBILIZED LEUKOPAKS AND NON-MOBILIZED LEUKOPAKS
TABLE 53 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2020–2027 (UNITS)
9.4 DISEASED LEUKOPAKS
9.4.1 RISING ADOPTION OF DISEASED LEUKOPAKS FOR CELL INTERACTION AND DRUG TOXICITY TO BOOST MARKET
TABLE 55 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 DISEASED LEUKOPAKS MARKET, BY REGION, 2020–2027 (UNITS)
9.5 ISOLATED PBMCS
9.5.1 INCREASING FOCUS OF RESEARCHERS ON CELL-BASED THERAPIES TO FUEL MARKET
TABLE 57 ISOLATED PBMCS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 ISOLATED PBMCS MARKET, BY REGION, 2020–2027 (UNITS)
10 LEUKOPAKS MARKET, BY INDICATION (Page No. - 142)
10.1 INTRODUCTION
FIGURE 53 GLOBAL NUMBER OF CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR CELLS
TABLE 59 LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
10.2 ACUTE LYMPHOCYTIC LEUKEMIA
10.2.1 RISING INCIDENCE OF DISEASE AND INCREASING RESEARCH IN CAR T-CELL THERAPY TO DRIVE MARKET
TABLE 60 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 MULTIPLE MYELOMA
10.3.1 INCREASED DIAGNOSTIC RATE TO FUEL SEGMENT
FIGURE 54 INCIDENCES OF MULTIPLE MYELOMA IN 2020
TABLE 61 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 NON-HODGKIN’S LYMPHOMA
10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO TREAT NON-HODGKIN’S LYMPHOMA TO BOOST SEGMENT
TABLE 62 LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY COUNTRY, 2020–2027 (USD MILLION)
10.5 CHRONIC LYMPHOCYTIC LEUKEMIA
10.5.1 RISE IN CASES OF CHRONIC LYMPHOCYTIC LEUKEMIA TO PROPEL SEGMENT
TABLE 63 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2020–2027 (USD MILLION)
10.6 PANCREATIC CANCER
10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO IDENTIFY PANCREATIC CANCER TO DRIVE SEGMENT
FIGURE 55 INCIDENCES OF PANCREATIC CANCER IN 2020
TABLE 64 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
10.7 HEPATOCELLULAR CARCINOMA
10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS AND HEPATOCELLULAR CARCINOMA TO FUEL SEGMENT
TABLE 65 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2020–2027 (USD MILLION)
10.8 OTHER INDICATIONS
TABLE 66 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
11 LEUKOPAKS MARKET, BY END USER (Page No. - 154)
11.1 INTRODUCTION
TABLE 67 LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2 ACADEMIC & RESEARCH INSTITUTES
11.2.1 INCREASING INDUSTRY−ACADEMIC PARTNERSHIPS FOR RESEARCH ON CELL-BASED CANCER THERAPIES TO DRIVE MARKET
TABLE 68 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT UTILIZING LEUKOPAKS AS STARTING MATERIAL TO PROPEL MARKET
FIGURE 56 PERCENTAGE OF ALL GLOBAL CAR-T DRUGS IN US V/S CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT
TABLE 69 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
11.4 CONTRACT RESEARCH ORGANIZATIONS
11.4.1 INCREASING SPONSORSHIP OF CLINICAL TRIALS TO FUEL SEGMENT
TABLE 70 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
12 LEUKAPHERESIS MARKET, BY REGION (Page No. - 159)
12.1 INTRODUCTION
FIGURE 57 LEUKAPHERESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 71 LEUKAPHERESIS MARKET, BY REGION, 2020–2027 (USD MILLION)
FIGURE 58 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 72 LEUKOPAKS MARKET, BY REGION, 2020–2027 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 59 NORTH AMERICA: LEUKAPHERESIS MARKET SNAPSHOT
TABLE 73 NORTH AMERICA: LEUKAPHERESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: LEUKAPHERESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 80 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.2.1 US
12.2.1.1 Presence of leading pharmaceutical and biotechnology companies to drive market
FIGURE 60 US: NUMBER OF REGISTERED CAR T THERAPY CLINICAL TRIALS (2022)
TABLE 82 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG)
TABLE 83 US: KEY MACROINDICATORS
TABLE 84 US: LEUKAPHERESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 86 US: LEUKAPHERESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 87 US: LEUKAPHERESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 88 US: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 US: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 90 US: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Rising prevalence of blood cancer to stimulate market growth
TABLE 91 CANADA: KEY MACROINDICATORS
TABLE 92 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 93 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 94 CANADA: LEUKAPHERESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 95 CANADA: LEUKAPHERESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 96 CANADA: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 98 CANADA: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.3 EUROPE
FIGURE 61 EUROPE: LEUKAPHERESIS MARKET SNAPSHOT
TABLE 99 EUROPE: NUMBER OF ONGOING CAR THERAPY CLINICAL TRIALS, BY COUNTRY, 2022
TABLE 100 EUROPE: LEUKAPHERESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 101 EUROPE: LEUKAPHERESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 104 EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 105 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 106 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 108 EUROPE: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.3.1 UK
12.3.1.1 Rising prevalence of target diseases to propel market
TABLE 109 UK: KEY MACROINDICATORS
TABLE 110 UK: LEUKAPHERESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 111 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 UK: LEUKAPHERESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 113 UK: LEUKAPHERESIS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 114 UK: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 UK: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 116 UK: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.3.2 GERMANY
12.3.2.1 Increasing research on cancer immunotherapies to boost market
TABLE 117 GERMANY: KEY MACROINDICATORS
TABLE 118 GERMANY: LEUKAPHERESIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 119 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 GERMANY: LEUKAPHERESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 121 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 122 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 123 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 124 GERMANY: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.3.3 SPAIN
12.3.3.1 Rising focus on development of novel CAR T-cell therapies to fuel market
TABLE 125 SPAIN: KEY MACROINDICATORS
TABLE 126 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 129 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 130 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 132 SPAIN: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.3.4 FRANCE
12.3.4.1 Developments in CAR-T cell therapy to drive market
TABLE 133 FRANCE: KEY MACROINDICATORS
TABLE 134 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 135 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 137 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 138 FRANCE: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 FRANCE: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 140 FRANCE: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.3.5 ITALY
12.3.5.1 Increasing geriatric population, rising research on CAR-T cell therapy, and growing cases of leukemia to boost market
TABLE 141 ITALY: COMMERCIAL CAR T-CELL THERAPIES APPROVED BY EMA (2022)
TABLE 142 ITALY: KEY MACROINDICATORS
TABLE 143 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 146 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 147 ITALY: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 149 ITALY: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.3.6 REST OF EUROPE
TABLE 150 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 153 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 154 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 155 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 156 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 62 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
TABLE 157 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 158 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 161 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 162 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 163 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.4.1 CHINA
12.4.1.1 China to witness highest growth during forecast period
FIGURE 63 CHINA: NUMBER OF CAR T-BASED CLINICAL TRIALS REGISTERED (2013–2020)
FIGURE 64 CHINA: NUMBER OF CAR-T THERAPY CLINICAL TRIALS, 2022
TABLE 166 CHINA: KEY MACROINDICATORS
TABLE 167 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 170 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 171 CHINA: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 172 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 173 CHINA: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.4.2 JAPAN
12.4.2.1 Research activities to focus on leukopak-based cell therapies
TABLE 174 JAPAN: KEY MACROINDICATORS
TABLE 175 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 176 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 178 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 179 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 180 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 181 JAPAN: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.4.3 REST OF ASIA PACIFIC
TABLE 182 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 185 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 186 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 188 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
12.5 REST OF THE WORLD
TABLE 189 REST OF THE WORLD: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 190 REST OF THE WORLD: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 191 REST OF THE WORLD: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 192 REST OF THE WORLD: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 193 REST OF THE WORLD: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 194 REST OF THE WORLD: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 195 REST OF THE WORLD: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION)
13 COMPETITIVE LANDSCAPE (Page No. - 216)
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS PRODUCTS MARKET
13.2.2 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKOPAKS MARKET
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 65 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF TOP FOUR MARKET PLAYERS
13.4 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS
TABLE 196 COMPANY PRODUCT FOOTPRINT
TABLE 197 COMPANY INDUSTRY FOOTPRINT
TABLE 198 COMPANY APPLICATION FOOTPRINT
TABLE 199 COMPANY REGION FOOTPRINT
13.5 LEUKAPHERESIS PRODUCTS MARKET SHARE (2021)
TABLE 200 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION
FIGURE 66 LEUKAPHERESIS PRODUCTS MARKET SHARE, BY KEY PLAYER (2021)
13.6 LEUKOPAKS MARKET SHARE (2021)
TABLE 201 LEUKOPAKS MARKET: DEGREE OF COMPETITION
FIGURE 67 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2021)
13.7 COMPANY EVALUATION QUADRANT (LEUKAPHERESIS PRODUCTS MARKET)
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
FIGURE 68 LEUKAPHERESIS PRODUCTS MARKET: COMPANY EVALUATION QUADRANT, 2021
13.8 COMPETITIVE EVALUATION QUADRANT FOR START-UPS/SMES (LEUKAPHERESIS MARKET) (2021)
TABLE 202 LEUKAPHERESIS MARKET: DETAILED LIST OF KEY START-UPS/SMES
13.8.1 PROGRESSIVE COMPANIES
13.8.2 DYNAMIC COMPANIES
13.8.3 STARTING BLOCKS
13.8.4 RESPONSIVE COMPANIES
FIGURE 69 LEUKAPHERESIS MARKET: SME/START-UP COMPANY EVALUATION QUADRANT, 2021
13.9 COMPETITIVE EVALUATION QUADRANT (LEUKOPAKS MARKET)
13.9.1 STARS
13.9.2 EMERGING LEADERS
13.9.3 PERVASIVE PLAYERS
13.9.4 PARTICIPANTS
FIGURE 70 LEUKOPAKS MARKET: COMPANY EVALUATION QUADRANT (2021)
13.1 COMPETITIVE SITUATIONS AND TRENDS
TABLE 203 PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–AUGUST 2022)
TABLE 204 DEALS (JANUARY 2019–AUGUST 2022)
TABLE 205 OTHER DEVELOPMENTS (JANUARY 2019–AUGUST 2022)
14 COMPANY PROFILES (Page No. - 236)
14.1 KEY PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
14.1.1 TERUMO BCT
TABLE 206 TERUMO CORPORATION: COMPANY OVERVIEW
FIGURE 71 TERUMO CORPORATION: COMPANY SNAPSHOT (2022)
14.1.2 FRESENIUS SE & CO. KGAA
TABLE 207 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
FIGURE 72 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2021)
14.1.3 HAEMONETICS CORPORATION
TABLE 208 HAEMONETICS CORPORATION: COMPANY OVERVIEW
FIGURE 73 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2022)
14.1.4 ASAHI KASEI CORPORATION
TABLE 209 ASAHI KASEI CORPORATION: COMPANY OVERVIEW
FIGURE 74 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2021)
14.1.5 MACOPHARMA SA
TABLE 210 MACOPHARMA SA: COMPANY OVERVIEW
14.1.6 MILTENYI BIOTEC
TABLE 211 MILTENYI BIOTEC: COMPANY OVERVIEW
14.2 OTHER PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
14.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.
TABLE 212 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
14.2.2 MEDICA SPA.
TABLE 213 MEDICA SPA: COMPANY OVERVIEW
14.2.3 PURIBLOOD MEDICAL CO. LTD.
TABLE 214 PURIBLOOD MEDICAL CO. LTD.: COMPANY OVERVIEW
14.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD.
TABLE 215 BEIJING ZKSK TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
14.2.5 SB-KAWASUMI LABORATORIES, INC.
TABLE 216 SB-KAWASUMI LABORATORIES, INC.: COMPANY OVERVIEW
14.2.6 NIKKISO CO., LTD.
TABLE 217 NIKKISO CO., LTD.: COMPANY OVERVIEW
FIGURE 75 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2021)
14.2.7 PALL CORPORATION
TABLE 218 PALL CORPORATION: COMPANY OVERVIEW
14.3 KEY PLAYERS (LEUKOPAKS MARKET)
14.3.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 219 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW
FIGURE 76 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
14.3.2 DISCOVERY LIFE SCIENCES, INC.
TABLE 220 DISCOVERY LIFE SCIENCES, INC.: COMPANY OVERVIEW
14.3.3 BIOIVT
TABLE 221 BIOIVT: COMPANY OVERVIEW
14.3.4 PRECISION FOR MEDICINE, INC.
TABLE 222 PRECISION FOR MEDICINE, INC.: COMPANY OVERVIEW
14.3.5 STEMEXPRESS, LLC
TABLE 223 STEMEXPRESS, LLC: COMPANY OVERVIEW
14.4 OTHER PLAYERS (LEUKOPAKS MARKET)
14.4.1 LONZA GROUP AG
TABLE 224 LONZA GROUP AG: COMPANY OVERVIEW
FIGURE 77 LONZA GROUP AG: COMPANY SNAPSHOT (2021)
14.4.2 CALTAG MEDSYSTEMS LIMITED
TABLE 225 CALTAG MEDSYSTEMS LIMITED: COMPANY OVERVIEW
14.4.3 ZENBIO, INC.
TABLE 226 ZENBIO, INC.: COMPANY OVERVIEW
14.4.4 INTELLIGENT TISSUE GROUP
14.4.5 TRINA BIOREACTIVES AG
14.4.6 ACCEGEN
14.4.7 FIRST CHOICE BIO LLC
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
15 APPENDIX (Page No. - 284)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the leukapheresis market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents for the leukapheresis products market is provided below:
Tiers are defined based on a company’s total revenue. As of 2021: Tier 1= >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3= To know about the assumptions considered for the study, download the pdf brochure A breakdown of the primary respondents for the leukopaks market is provided below: Tiers are defined based on a company’s total revenue. As of 2021: Tier 1= >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3= The total size of the leukapheresis market was arrived at after data triangulation from three different approaches for each of the two sub-markets (leukapheresis products market and leukopaks market) as mentioned below. Approach to calculate the revenue of different players in the leukapheresis products market The size of the global leukapheresis products market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global leukapheresis products market was derived. Approach to derive the market size and estimate market growth The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate. The same approach was used for the leukopaks market. After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Market Size Estimation
Data Triangulation
Objectives of the Study
Available Customizations
Geographic Analysis
Generating Response ...
Growth opportunities and latent adjacency in Leukapheresis Market